Proteasome inhibitor MG132 induces NAG-1/GDF15 expression through the p38 MAPK pathway in glioblastoma cells

Biochemical and Biophysical Research Communications

Volumn 430, Issue 4, 2013, Pages 1277-1282

  Shimizu, Sachie ^a,b   Kadowaki, Mitsutoshi ^b   Yoshioka, Hiroki ^b   Kambe, Atsushi ^b   Watanabe, Takashi ^b   Kinyamu, H Karimi ^a   Eling, Thomas E ^a  

^a NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES   (United States)

^b TOTTORI UNIVERSITY   (Japan)

Author keywords

GBM; GDF 15; Glioblastoma; MG132; NAG 1; NAG 1 GDF15; P38 MAPK

Indexed keywords

BENZYLOXYCARBONYLLEUCYLLEUCYLLEUCINAL; GROWTH DIFFERENTIATION FACTOR 15; MESSENGER RNA; MITOGEN ACTIVATED PROTEIN KINASE P38; NONSTEROIDAL ANTIINFLAMMATORY DRUG ACTIVATED GENE 1; TUMOR SUPPRESSOR PROTEIN; UNCLASSIFIED DRUG;

ARTICLE; ENZYME ACTIVATION; GLIOBLASTOMA; HALF LIFE TIME; PRIORITY JOURNAL; PROMOTER REGION; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; PROTEIN SECRETION;

ANIMALS; BRAIN NEOPLASMS; CYSTEINE PROTEINASE INHIBITORS; GLIOBLASTOMA; GROWTH DIFFERENTIATION FACTOR 15; HUMANS; LEUPEPTINS; MICE; P38 MITOGEN-ACTIVATED PROTEIN KINASES; PROMOTER REGIONS, GENETIC; PROTEASOME INHIBITORS; RNA STABILITY; RNA, MESSENGER;

MUS MUSCULUS;

EID: 84872849478     PISSN: 0006291X     EISSN: 10902104     Source Type: Journal    
DOI: 10.1016/j.bbrc.2012.11.137     Document Type: Article

References (22)

1. Polivka J., Polivka J., Rohan V., Topolcan O., Ferda J. New molecularly targeted therapies for glioblastoma multiforme. Anticancer Res. 2012, 32:2935-2946.
2. Frankland-Searby S., Bhaumik S.R. The 26S proteasome complex: an attractive target for cancer therapy. Biochim. Biophys. Acta 1825, 2012:64-76.
3. Yin D., Zhou H., Kumagai T., Liu G., Ong J.M., Black K.L., Koeffler H.P. Proteasome inhibitor PS-341 causes cell growth arrest and apoptosis in human glioblastoma multiforme (GBM). Oncogene 2005, 24:344-354.
4. Zanotto-Filho A., Braganhol E., Battastini A.M., Moreira J.C. Proteasome inhibitor MG132 induces selective apoptosis in glioblastoma cells through inhibition of PI3K/Akt NFkappaB pathways mitochondrial dysfunction and activation of p38-JNK1/2 signaling. Invest. New Drugs 2012.
5. Kubicek G.J., Werner-Wasik M., Machtay M., Mallon G., Myers T., Ramirez M., Andrews D., Curran W.J., Dicker A.P. Phase I trial using proteasome inhibitor bortezomib and concurrent temozolomide and radiotherapy for central nervous system malignancies. Int. J. Radiat. Oncol., Biol., Phys. 2009, 74:433-439.
6. Baek S.J., Eling T.E. Changes in gene expression contribute to cancer prevention by COX inhibitors. Prog. Lipid Res. 2006, 45:1-16.
7. Eling T.E., Baek S.J., Shim M., Lee C.H. NSAID activated gene (NAG-1), a modulator of tumorigenesis. J. Biochem. Mol. Biol. 2006, 39:649-655.
8. Shim M., Eling T.E. Vitamin E succinate induces NAG-1 expression in a p38 kinase-dependent mechanism. Mol. Cancer Ther. 2008, 7:961-971.
9. Wang X., Baek S.J., Eling T. COX inhibitors directly alter gene expression: role in cancer prevention?. Cancer Metastasis Rev. 2011, 30:641-657.
10. Mimeault M., Batra S.K. Divergent molecular mechanisms underlying the pleiotropic functions of macrophage inhibitory cytokine-1 in cancer. J. Cell. Physiol. 2010, 224:626-635.
11. Yoshioka H., Kamitani H., Watanabe T., Eling T.E. Nonsteroidal anti-inflammatory drug-activated gene (NAG-1/GDF15) expression is increased by the histone deacetylase inhibitor trichostatin A. J. Biol. Chem. 2008, 283:33129-33137.
12. Yamaguchi K., Lee S.H., Eling T.E., Baek S.J. A novel peroxisome proliferator-activated receptor gamma ligand, MCC-555, induces apoptosis via posttranscriptional regulation of NAG-1 in colorectal cancer cells. Mol. Cancer Ther. 2006, 5:1352-1361.
13. Kadowaki M., Yoshioka H., Kamitani H., Watanabe T., Wade P.A., Eling T.E. DNA methylation-mediated silencing of nonsteroidal anti-inflammatory drug-activated gene (NAG-1/GDF15) in glioma cell lines. Int. J. Cancer 2012, 130:267-277.
14. Baek S.J., Okazaki R., Lee S.H., Martinez J., Kim J.S., Yamaguchi K., Mishina Y., Martin D.W., Shoieb A., McEntee M.F., Eling T.E. Nonsteroidal anti-inflammatory drug-activated gene-1 over expression in transgenic mice suppresses intestinal neoplasia. Gastroenterology 2006, 131:1553-1560.
15. Baek S.J., Horowitz J.M., Eling T.E. Molecular cloning and characterization of human nonsteroidal anti-inflammatory drug-activated gene promoter. Basal transcription is mediated by Sp1 and Sp3. J. Biol. Chem. 2001, 276:33384-33392.
16. Mazroui R., Di Marco S., Kaufman R.J., Gallouzi I.E. Inhibition of the ubiquitin-proteasome system induces stress granule formation. Mol. Biol. Cell. 2007, 18:2603-2618.
17. Nabors L.B., Gillespie G.Y., Harkins L., King P.H. HuR, a RNA stability factor, is expressed in malignant brain tumors and binds to adenine- and uridine-rich elements within the 3' untranslated regions of cytokine and angiogenic factor mRNAs. Cancer Res. 2001, 61:2154-2161.
18. Weng M.S., Ho Y.S., Lin J.K. Chrysin induces G1 phase cell cycle arrest in C6 glioma cells through inducing p21Waf1/Cip1 expression: involvement of p38 mitogen-activated protein kinase. Biochem. Pharmacol. 2005, 69:1815-1827.
19. Jennings M.T., Pietenpol J.A. The role of transforming growth factor beta in glioma progression. J. Neurooncol. 1998, 36:123-140.
20. Albertoni M., Shaw P.H., Nozaki M., Godard S., Tenan M., Hamou M.F., Fairlie D.W., Breit S.N., Paralkar V.M., de Tribolet N., Van Meir E.G., Hegi M.E. Anoxia induces macrophage inhibitory cytokine-1 (MIC-1) in glioblastoma cells independently of p53 and HIF-1. Oncogene 2002, 21:4212-4219.
21. Roth P., Junker M., Tritschler I., Mittelbronn M., Dombrowski Y., Breit S.N., Tabatabai G., Wick W., Weller M., Wischhusen J. GDF-15 contributes to proliferation and immune escape of malignant gliomas. Clin. Cancer Res. 2010, 16:3851-3859.
22. Shnaper S., Desbaillets I., Brown D.A., Murat A., Migliavacca E., Schluep M., Ostermann S., Hamou M.F., Stupp R., Breit S.N., de Tribolet N., Hegi M.E. Elevated levels of MIC-1/GDF15 in the cerebrospinal fluid of patients are associated with glioblastoma and worse outcome. Int. J. Cancer 2009, 125:2624-2630.